Anal Intraepithelial Neoplasia in Heterosexual and Homosexual HIV-Positive Men with Access to Antiretroviral Therapy
|
|
- Caitlin Ryan
- 6 years ago
- Views:
Transcription
1 MAJOR ARTICLE Anal Intraepithelial Neoplasia in Heterosexual and Homosexual HIV-Positive Men with Access to Antiretroviral Therapy T. J. Wilkin, 1 S. Palmer, 2 K. F. Brudney, 3 M. A. Chiasson, 3,5 and T. C. Wright 4 1 Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, 2 New York Presbyterian Hospital, 3 Division of Infectious Diseases and 4 Department of Pathology, Columbia University College of Physicians and Surgeons, and 5 Medical and Health Research Association of New York City, New York, New York Background. Studies of human immunodeficiency virus (HIV) positive men have demonstrated high rates of anal intraepithelial neoplasia (AIN), a precursor to anal carcinoma, mostly in white homosexual men and men not receiving effective antiretroviral therapy (ART). Methods. Ninety-two participants 53% Latino, 36% African American, and 40% without a history of receptive anal intercourse (RAI) were evaluated with a behavioral questionnaire, liquid-based anal cytological testing, Hybrid Capture 2 human papillomavirus (HPV) DNA assay and polymerase chain reaction, and anal colposcopy with biopsy of lesions. Results. High-risk HPV DNA was identified in 61%, and this was associated with a history of RAI (78% vs. 33%; P!.001); 47% had abnormal cytological results, and 40% had AIN on biopsy. In multivariate analysis, both were associated with a history of RAI (odds ratio [OR], 10 [ P!.001] and OR, 3.6 [ P p.02], respectively) and lower nadir CD4 + cell counts ( P p.06 and P p.01 ). Current ART use was protective (OR, 0.09; P!.01 and OR, 0.18; P p.02). Conclusions. Although anal infections with high-risk HPV and AIN in HIV-positive men are associated with a history of RAI, both conditions are commonly identified in HIV-positive men without this history. Both lower nadir CD4 + cell counts and lack of current ART were associated with AIN but not with the detection of anal HPV. Anal carcinoma is strongly related to infection with high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) of human papillomavirus (HPV), as has been seen for cervical, vaginal, vulvar, and penile cancer [1 5]. The incidence of anal cancer in men who have sex with men (MSM) is estimated to be 35 cases/ 100,000 person-years [6]. This incidence is comparable to that observed for cervical cancer before the intro- Received 20 February 2004; accepted 13 May 2004; electronically published 1 October Presented in part: 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 2003 (abstract 819). Financial support: National Cancer Institute, National Institutes of Health (National Research Service Award); Columbia-Rockefeller Center for AIDS Research (Research Development Grant). Reprints or correspondence: Dr. Timothy J. Wilkin, Div. of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, 119 W. 24th St., Ground Floor, New York, NY (tiw2001@med.cornell.edu). The Journal of Infectious Diseases 2004; 190: by the Infectious Diseases Society of America. All rights reserved /2004/ $15.00 duction of routine Papanicalaou screening. The rate of anal cancer is twice as high in HIV-positive than in HIV-negative MSM [7]. Investigators have used anal cytological testing and colposcopy to test for anal intraepithelial neoplasia (AIN), which are precancerous lesions that can progress to invasive cancer. A high incidence and prevalence of AIN have been reported in HIV-positive and -negative MSM [8 12]. These studies have included predominantly white men and have not included HIV-positive men without a history of sex with men, despite some evidence that these men are also at increased risk for anal cancer [7]. Moreover, few studies have directly evaluated the effect that antiretroviral therapy (ART) has on either anal HPV infection or AIN [13 15]. Our study was performed to determine the prevalence of anal HPV infection and AIN in a diverse population of HIV-positive men, including men of color, men with and without a history of sex with other men, and men receiving or not receiving effective ART. AIN in HIV-Positive Men JID 2004:190 (1 November) 1685
2 SUBJECTS, MATERIALS, AND METHODS Study population. Participants were enrolled from June 2001 through March Clinicians referred men from the Columbia-Presbyterian Medical Center Infectious Diseases Clinic, an urban clinic that serves 1000 HIV-positive patients. The racial/ ethnic breakdown of the referring clinic is 60% Hispanic or Latino, 35% African American, and 5% white. Sixty percent of the patients are male, 30% of whom self-identify as gay or homosexual. Exclusion criteria included a platelet count!75,000 cells/mm 3 and an absolute neutrophil count!1000 cells/mm 3. Primary care providers from the referring clinic were asked to refer men without regard to the patient s previous history of genital or perianal condyloma, other sexually transmitted diseases, or sexual behavior. Informed consent was obtained from all patients. Human-experimentation guidelines of the US Department of Health and Human Services (DHHS) and those of Columbia University were followed during our study. Behavioral questionnaire. An investigator who was not the participant s primary care provider administered a questionnaire that elicited a detailed sexual history, with questions on the history of receptive anal intercourse (RAI) and participantdefined sexual behavior (heterosexual, homosexual, or bisexual), lifetime number of female partners, lifetime number of male partners, lifetime number of RAI partners, age at onset of sexual activity, receptive oral-anal contact, and insertion of fingers or sex toys during sexual intercourse, as well as questions on tobacco use and history of sexually transmitted diseases. Cytological testing. Anal cytological results were evaluated by use of 2 different methods: (1) a Dacron swab premoistened in saline was used to obtain cells from the anal canal that were then spread onto a glass slide and fixed with spray cytology fixative; and (2) a conical cytobrush with a blunt tip (cervical specimen collection kit; Digene) that was premoistened in saline was used to obtain cells from the anal canal that were subsequently transferred to a liquid-based cytology vial (Thin Prep; Cytyc) and processed according to the manufacturer s instructions for cervical cytological testing. The liquid-based cytological testing led to an interpretable result more often than the conventional method and was chosen as the outcome of interest for the analysis. HPV testing. After the cytological specimens were obtained, an additional cytobrush was used to collect a sample from the anal canal for the Hybrid Capture 2 (hc2) HPV DNA assay for high-risk types of HPV (Digene). The HPV types present in samples found to contain high-risk HPV DNA when hc2 was used were determined by use of polymerase chain reaction (PCR) with consensus Ll PGM09/11 primers and reverse-line blot hybridization (provided by Janet Kornegay, Roche Molecular Diagnostics, Pleasanton, CA). For PCR, DNA was isolated by use of spin columns (Qiagen) from an aliquot of the liquid cytological medium. Anal colposcopy. Anal colposcopy was performed as described elsewhere on all participants [16]. In brief, a disposable anoscope coated with a mixture of surgical lubricant and 2% tetracaine gel was used to introduce an applicator stick wrapped in gauze that had been soaked in 3% acetic acid, which was then left in place for 2 min. A colposcope was then used to view the walls of the anal canal under magnification. Any areas of acetowhitening or vascular changes suspicious for AIN were sampled by use of cervical biopsy forceps. If no visible lesions were seen, then no biopsy was done. Subsequently, if either of the 2 anal cytological specimens was diagnosed as atypical squamous cells (ASC) or greater and no biopsy had been performed at the time of anal colposcopy, the participant was asked to return for repeat anal colposcopy and biopsy. Pathologic classification. The liquid-based and conventional cytological specimens were interpreted by use of the Bethesda criteria [17]. Anal biopsies were interpreted by use of a 2-tiered terminology (low-grade and high-grade AIN) with criteria established elsewhere for cervical biopsy samples [18]. Cytological specimens were initially screened by a cytotechnologist, with the final interpretation being made by a single pathologist who was blinded to all clinical information and other pathological results. Medical record review. An investigator performed a standardized review of the participants medical records to ascertain the nadir CD4 + cell count (i.e., the lowest CD4 + cell count recorded), current CD4 + cell count and log 10 HIV RNA load, current receipt of ART, and length of time of having an HIV RNA load!400 copies/ml. Statistical analyses. The outcomes of interest were the presence of high-risk HPV DNA according to hc2 (relative light units 1 were considered to indicate positivity), abnormal results of liquid-based cytological testing (atypical squamous cells or low- or high-grade squamous intraepithelial lesions), and AIN according to the results of histological testing. A participant was classified as having normal results in the histologybased analysis if no biopsy was performed because of a lack of visible lesions on anal colposcopy with normal cytological results or if there was no evidence of condyloma accuminata, AIN, or cancer on any of the biopsy specimens. If the participant had an abnormal cytological result but did not return for the biopsy, he was excluded from the histology-based analysis. The association of univariate predictors was calculated by use of the x 2 test. Multivariate models were constructed by use of logistic regression, and the same model was selected for all 3 outcomes (the presence of high-risk HPV, abnormal cytological result, and AIN according to the results of histological testing). Current and nadir CD4 + cell counts were analyzed as continuous variables after log transformation to normalize the dis JID 2004:190 (1 November) Wilkin et al.
3 tribution. All statistical analyses were performed by use of SAS software (version 8.02; SAS Institute). RESULTS Study population. Table 1 describes the study population of 92 men. Eighty-nine percent were either Latino or African American. Seventy-five (82%) were receiving ART at the time of the study, and most had a good virologic response (61% had an HIV RNA load!400 copies/ml). Of the 17 men not receiving ART, 7 had a CD4 + count!350 cells/mm 3 and therefore met DHHS criteria for consideration for starting ART [19]. Sixty percent of participants reported a history of RAI, including all 46 homosexual men, 8 of 10 bisexual men, and 1 of 35 heterosexual men. High-risk HPV analyses. Overall, 56 (61%) of 92 participants were found to have high-risk HPV DNA according to the results of hc2. The strongest predictor of positivity for high-risk HPV DNA was a history of RAI (table 2). Age 40 years was also associated with the detection of high-risk HPV DNA. In the multivariate analysis (table 2), only a history of RAI remained significant. There was a trend toward nadir CD4 + cell count being associated in the multivariate analysis. Other factors such as race/ethnicity (Hispanic/Latino, African American, or white/ other); tobacco use (current or lifetime); total number of sex partners; number of female, male, or RAI partners; history of receptive oral-anal intercourse or insertion of fingers or sex toys during intercourse; and age at onset of sexual activity were not associated with high-risk HPV DNA positivity. Neither current plasma HIV RNA load, current CD4 + cell count, current receipt of ART, nor time receiving ART was associated with high-risk HPV. HPV DNA PCR was attempted on the 56 participants who tested positive for HPV DNA by hc2. Forty-six had high-risk HPV DNA typeable by PCR. Overall, 17 of 92 participants had multiple types of high-risk HPV by PCR. The most common types of high-risk HPV detected were 16 (17% of participants), 52 (10%), 18 (8%), and 45 (8%). Cytological analyses. Seven participants were excluded from the cytological analysis (5 had specimens unavailable for analysis, and 2 had liquid-based cytological specimens classified as being unsatisfactory for evaluation). Of the remaining participants, 47% (40/85) had abnormal results by liquid-based cytological testing: 18% ASC of undetermined significance (ASC- US), 24% low-grade squamous intraepithelial lesions (SILs), and 6% high-grade SILs. A history of RAI was the strongest predictor of abnormal cytological results in the univariate analysis. Other predictors of abnormal results in the univariate analysis were age 40 years and no current ART use (table 2). The current CD4 + cell count was not related to abnormal cytological results. In the multivariate model, RAI and no current ART use were significantly associated with abnormal cytological results, and nadir CD4 + cell count exhibited a trend toward Table 1. Demographics, immunologic factors, and sexual history of the study population. Characteristic Value Demographics Race/ethnicity Hispanic/Latino 49 (53) African American 33 (36) White 7 (8) Other 3 (3) Age 30, years 8 (9) 31 40, years 25 (27) 41 50, years 35 (38) 150, years 24 (26) Reported HIV risk factor a Sex with men 55 (60) Sex with women 36 (39) Intravenous drug use 8 (9) Blood transfusion 2 (2) Immunologic factors Current plasma HIV RNA load!50, copies/ml 46 (50) , copies/ml 10 (11) ,000, copies/ml 18 (20) 110,000, copies/ml 18 (20) Nadir CD4 + cell count b 50, cells/mm 3 31 (34) , cells/mm 3 28 (31) , cells/mm 3 19 (21) 1350, cells/mm 3 13 (14) Current antiretroviral therapy use Yes 75 (82) No 17 (18) Sexual history Participant-defined sexuality Heterosexual 36 (39) Homosexual 46 (50) Bisexual 10 (11) Sex with women ever Yes 80 (87) No 12 (13) Sex with men ever b Yes 62 (68) No 29 (32) History of receptive anal intercourse ever b Yes 55 (60) No 36 (40) No. of lifetime sex partners, median (25th 75th interquartile range) Heterosexual 35 (16 97) Homosexual 98 (23 235) Bisexual 57 (30 107) NOTE. Data are no. (%) of women, except where noted. a Participants could report multiple risk factors. b These categories do not total 92 because of missing data. being associated (table 2). High-risk HPV was strongly associated with abnormal cytological results 72% (38/53) of those with high-risk HPV had abnormal results, compared with only 6% (2/32) without high-risk HPV. When we restricted the analysis to those with high-risk HPV DNA according to hc2, RAI and no current ART use remained significantly related to abnormal AIN in HIV-Positive Men JID 2004:190 (1 November) 1687
4 Table 2. Univariate and multivariate predictors of anal human papillomavirus (HPV) infection, abnormal cytological results, and anal intraepithelial neoplasia (AIN) on histological results. Anal HPV infection Abnormal cytological results a AIN on histological results No. with anal HPV infection/ Characteristic total no. (%) Univariate analysis, OR (95% CI); P Multivariate analysis, Adjusted OR (95% CI); P No. with abnormal cytological results/total no. (%) Univariate analysis, OR (95% CI); P Multivariate analysis, Adjusted OR (95% CI); P No. with AIN on histological results/total no. (%) Univariate analysis, OR (95% CI); P Multivariate analysis, Adjusted OR (95% CI); P History of RAI b Yes 43/55 (78) 7.2 (2.8 18);! (2.6 20);! /51 (65) 8.3 (2.9 24);! (3 36);! /52 (52) 3.6 ( ); (1.2 11);.02 No 12/36 (33) 6/33 (18) 8/35 (23) Current use of ART c Yes 45/75 (60) 0.82 ( ); (0.12 2);.3 29/70 (41) 0.26 ( ); (.02.51); /71 (37) 0.45 ( ); (.04.75);.02 No 11/17 (65) 11/15 (73) 9/16 (56) Age 40 years Yes 26/33 (78) 3.6 ( ); (0.8 7);.12 20/31 (65) 3.1 ( ); ( );.18 19/31 (61) 4 (1.6 10); ( );.04 No 30/59 (51) 20/54 (37) 16/56 (29) Nadir CD4 + cell count c,d NA 0.86 ( ); ( );.08 NA 0.98 ( ); ( );.06 NA 0.76 ( ); ( );.01 NOTE. The multivariate analyses are adjusted for the 4 predictors presented in the table. ART, antiretroviral therapy; CI, confidence interval; NA, not applicable; OR, odds ratio; RAI, receptive anal intercourse. Includes atypical squamous cells and low- or high-grade squamous intraepithelial lesions. b Data on history of RAI were missing for 1 subject. An OR!1 indicates that the factor is associated with a lower odds of having the outcome of interest. d Modeled as a continuous variable after log transformation to normalize the distribution. a c
5 cytological results, and nadir CD4 + cell count exhibited a trend (table 3). Histological analyses. Five participants were excluded from the histological analysis (2 did not have a biopsy despite abnormal cytological results, and 3 had unavailable or unsatisfactory cytological results with no biopsy). Some 40% (35/87) of participants had AIN on histology (31% low-grade AIN and 9% high-grade AIN). A history of RAI and age 40 years were related to AIN on histological testing in the univariate analysis (table 2). Current CD4 + cell count was not related to abnormal histological results. In the multivariate analysis, lower nadir CD4 + cell count and no current ART use, in addition to RAI and younger age, were associated with AIN being found by histology (table 3). The association of ART with AIN was confounded by nadir CD4 + cell count. The mean nadir CD4 + count of participants who were receiving ART (63 cells/mm 3 ) was lower than that of participants not receiving ART (290 cells/mm 3 ). The association of ART use and AIN was apparent only when controlling for nadir CD4 + cell count. High-risk HPV was strongly associated with AIN on histology 64% (34/ 53) of those with high-risk HPV had AIN, compared with only 3% (1/33) without high-risk HPV. When we restricted the analysis to those with high-risk HPV DNA according to hc2, nadir CD4 + cell count and no current ART use remained significantly related to AIN on histology, but RAI did not (table 3). DISCUSSION We have demonstrated a high prevalence of AIN and anal HPV in a predominantly Latino and African American group of HIVpositive men. Although a history of RAI was strongly related to AIN, there was a significant prevalence (23%) in men without this history, 94% of whom self-identified as heterosexual. This suggests that RAI is not a necessary factor for anal HPV infection and AIN and is supported by the results of a recent study that found a high prevalence of high-grade AIN (18%) in heterosexual HIV-positive men with a history of intravenous drug use [20] and a study that found that husbands of women with cervical cancer are at an increased risk for anal cancer [21]. In a study of HIV-positive women, 23% of participants without a history of RAI were found to have abnormal anal cytological results [22]. The questionnaire used in the present study, which provides a much more detailed sexual history than would be obtained in clinical practice, did not identify factors that reliably discriminated those at low risk for AIN. These data strongly suggest that, if instituting an anal cancer screening program, all HIV-positive men, regardless of sexual orientation, should be offered participation. Other researchers have made a similar claim to include all HIV-positive women in anal cancer screening programs, regardless of history of RAI [23]. Our study also found that the nadir CD4 + cell count was significantly associated with AIN on histology in the multivariate analysis. Lower CD4 + cell counts have been demonstrated elsewhere to be associated with AIN [10, 24], and our results suggest that a lower nadir CD4 + cell count remains an independent risk factor for AIN, despite the use of effective ART. Other investigators have shown that, among patients with similar CD4 + cell counts, those with a lower nadir CD4 + cell count have decreased proliferative T cell responses, which are indicative of immune suppression, compared with those who have a higher nadir CD4 + cell count [25]. Although immune recovery sufficient for protection against opportunistic infections and other AIDS-defining illnesses generally occurs with ART, regardless of the nadir CD4 + cell count at the time of initiation, this suggests that a less-pronounced immunodeficiency related to lower nadir CD4 + cell counts remains. These immune deficits may allow the development of AIN in persons with persistent infection with high-risk types of HPV and may confer an elevated risk of invasive cancer. Current use of ART was significantly associated with a lower prevalence of abnormal cytological results and AIN in the multivariate model. Substituting current plasma HIV RNA load for ART use yielded similar results (data not shown). This associ- Table 3. Multivariate predictors of abnormal cytology and anal intraepithelial neoplasia (AIN) according to histological results in those with high-risk human papillomavirus (HPV) infection according to the results of Hybrid Capture 2 assay. Characteristic Abnormal cytological results a AIN on histological results Adjusted OR (95% CI) P Adjusted OR (95% CI) P History of RAI, yes vs. no 5.7 (1.1 29) ( ).4 Current use of ART, yes vs. no b 0.06 ( )! ( ).03 Age, 40 vs. 140 years 1.8 ( ) (0.9 13).06 Nadir CD4 + cell count b,c 0.6 ( ) ( ).03 NOTE. ART, antiretroviral therapy; CI, confidence interval; NA, not applicable; OR, odds ratio; RAI, receptive anal intercourse. a Includes atypical squamous cells and low- or high-grade squamous intraepithelial lesions. b An OR!1 indicates that the factor is associated with lower odds of having the outcome of interest. c Modeled as a continuous variable after log transformation to normalize the distribution. AIN in HIV-Positive Men JID 2004:190 (1 November) 1689
6 ation was confounded in the univariate analysis by the nadir CD4 + cell count. Participants receiving ART had a lower nadir CD4 + cell count than those not receiving ART. This is to be expected, given that a low CD4 + cell count is a major consideration for starting ART. Studies of ART and cervical intraepithelial neoplasia have found conflicting results, with some studies finding a benefit of ART for intraepithelial neoplasia [26, 27] but not others [28]. In studies that have shown a benefit for patients receiving ART, there is no evidence to suggest that cervical cancer screening guidelines for HIV-positive women should be modified. Previous studies have not found a relationship between the use of ART and AIN [13 15]. If physicians choose to screen for anal cancer, there should be no modification based on ART use. The initial paradigm for the use of potent combinations of ART was to provide treatment early during the course of HIV infection, when the CD4 + count decreased to!500 cells/mm 3 [29]. As a result of a growing realization of the acute and chronic toxicities of these regimens, recent major US national consensus guidelines for the treatment of HIV infection have favored delaying ART until later during the course of HIV infection, as the CD4 + count approaches 200 cells/mm 3 [19, 30]. However, further research is needed to determine whether the delayed initiation of ART and lower nadir CD4 + cell counts will have a deleterious effect on HPV-associated malignancy. Although ART was associated with a decreased prevalence of AIN, it was not associated with a decreased prevalence of high-risk HPV. This is interesting and may tell us something about the relationship between persistent HPV infection and neoplasia in HIV-positive individuals. We have previously reported that, in HIV-positive women, the persistence of HPV shedding into genital secretions was increased, compared with HIV-negative control subjects, even at relatively high CD4 + cell counts [31]. The risk of cervical intraepithelial neoplasia in those women with persistent HPV infection increased with lower CD4 + cell counts. Consistent with this, the present results suggest that ART may reduce the prevalence of AIN in those men with persistent HPV infection but does not appreciably reduce HPV persistence itself. Prospective cohort studies are needed to definitively answer this question. Infection with high-risk HPV appears to be a necessary factor for having abnormal cytological results or AIN according to histological testing. When the analyses were restricted to participants with high-risk HPV, the odds ratios for a history of RAI to these outcomes were reduced by 50%, which suggests that these relationships are partially mediated by increased exposure to HPV. In contrast, the odds ratios for nadir CD4 + cell count and ART did not change appreciably. There are several limitations to our study. Primary care providers were more likely to refer subjects who reported sex with other men, which led to an overestimate of the overall prevalence of high-risk HPV, abnormal cytological results, and AIN. Providers may have been more likely to refer subjects with a prior history of genital condyloma, which may limit the generalizability of our study. Participants may have inaccurately reported their history of RAI, even though participants could report such a history even when they self-identified as heterosexual. The cross-sectional design does not establish temporality, so it is impossible to know whether ART is associated with decreased progression of AIN or increased regression. Although a definitive diagnosis of AIN is based on histological results, we presented cytological results to illustrate the percentage of patients screened in a clinical setting that would require anal colposcopy. The histological outcome may underestimate the prevalence of AIN because of the limited number of anal biopsies performed in any given patient. Because of the limited number of cases of high-grade AIN that were identified, any grade of biopsy-confirmed AIN was used as our histological end point. High-grade AIN is the condition that is thought to precede invasive cancer and is the lesion that requires intervention. Although 150% of low-grade AINs will progress within 2 years [11], high-grade AIN would be the ideal outcome for these analyses. Our study does not provide direct evidence as to whether screening for AIN is clinically beneficial. An anal cancer screening program should identify patients with high-grade AIN for which there is a surgical intervention, which will reduce the risk of invasive carcinoma. Studies by Goldie et al. [32, 33] have suggested that cytological screening for anal cancer is costeffective for HIV-positive and -negative men. However, those studies assumed reasonable levels of effectiveness for the treatment of high-grade AIN. There are few data on the efficacy of various treatment modalities for high-grade AIN, including the topical application of 80% trichloroacetic acid or liquid nitrogen, electrocautery, infrared coagulation, or laser ablation. One study of HIV-positive and -negative men evaluated the surgical excision of extensive high-grade AIN that was too large for topical therapy with 80% trichloroacetic acid [34]. The surgery was effective in removing AIN and preventing recurrent lesions in all 8 HIV-negative men studied (median follow-up, 32 months) but was ineffective for HIV-positive men, with 23 of 29 having persistent or recurrent high-grade AIN (median follow-up, 29 months). The effect of ART use on the response to treatment of high-grade AIN is unknown. More information is needed on the recurrence rates of high-grade AIN and the relative morbidities for the various techniques before widespread screening programs can be implemented. Acknowledgments We acknowledge Scott Hammer, Division of Infectious Diseases, Columbia University, for his support and mentorship; and Heino Meyer- Bahlburg, HIV Center for Clinical and Behavioral Research, New York 1690 JID 2004:190 (1 November) Wilkin et al.
7 State Psychiatric Institute and Columbia University, for his help in developing the behavioral questionnaire. References 1. Zaki SR, Judd R, Coffield LM, Greer P, Rolston F, Evatt BL. Human papillomavirus infection and anal carcinoma: retrospective analysis by in situ hybridization and the polymerase chain reaction. Am J Pathol 1992; 140: Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: Ansink AC, Heintz AP. Epidemiology and etiology of squamous cell carcinoma of the vulva. Eur J Obstet Gynecol Reprod Biol 1993; 48: Daling JR, Madeleine MM, Schwartz SM, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002; 84: Maden C, Sherman KJ, Beckmann AM, et al. History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst 1993; 85: Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987; 317: Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351: Kiviat NB, Critchlow CW, Holmes KK, et al. Association of anal dysplasia and human papillomavirus with immunosuppression and HIV infection among homosexual men. AIDS 1993; 7: Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998; 12: Palefsky JM, Holly EA, Ralston ML, et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: Palefsky JM, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: Friedman HB, Saah AJ, Sherman ME, et al. Human papillomavirus, anal squamous intraepithelial lesions, and human immunodeficiency virus in a cohort of gay men. J Infect Dis 1998; 178: Palefsky JM, Holly EA, Ralston ML, et al. Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Syndr 2001; 28: Palefsky J, Holly E, Ralston M, et al. Effect of HAART on incidence of anal intraepithelial neoplasia grade 3 among HIV-positive men who have sex with men (abstract LbOr21). In: Program and abstracts of the 2002 International AIDS Conference (Barcelona) Geneva: International AIDS Society: Piketty C, Darragh TM, Heard I, et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis 2004; 31: Jay N, Berry JM, Hogeboom CJ, Holly EA, Darragh TM, Palefsky JM. Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology. Dis Colon Rectum 1997; 40: Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. Bethesda 2001 Workshop. JAMA 2002; 287: Wright TC, Ferenczy AF, Kurman RJ. Precancerous lesions of the cervix. In: Kurman RJ, ed. Blaustein s pathology of the female genital tract. 4th ed. New York: Springer-Verlag, 1994: US Department of Health and Human Services, Panel on Clinical Practices for Treatment of HIV Infection: guidelines for the use of antiretrovirals in HIV-infected adults and adolescents. Available at: Accessed 6 January Piketty C, Darragh TM, Costa MD, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003; 138: Hemminki K, Dong C. Cancer in husbands of cervical cancer patients. Epidemiology 2000; 11: Hillemanns P, Ellerbrock TV, McPhillips S, et al. Prevalence of anal human papillomavirus infection and anal cytologic abnormalities in HIV-seropositive women. AIDS 1996; 10: Palefsky JM. Anal squamous intraepithelial lesions in human immunodeficiency virus positive men and women. Semin Oncol 2000; 27: Critchlow CW, Hawes SE, Kuypers JM, et al. Effect of HIV infection on the natural history of anal human papillomavirus infection. AIDS 1998; 12: Sieg SF, Mitchem JB, Bazdar DA, Lederman MM. Close link between CD4 + and CD8 + T cell proliferation defects in patients with human immunodeficiency virus disease and relationship to extended periods of CD4 + lymphopenia. J Infect Dis 2002; 185: Minkoff H, Ahdieh L, Massad LS, et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 2001; 15: Heard I, Tassie JM, Kazatchkine MD, Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS 2002; 16: Lillo FB, Ferrari D, Veglia F, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001; 184: Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in JAMA 1998; 280: Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society USA Panel. JAMA 2002; 288: Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997; 337: Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999; 281: Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM. Costeffectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus negative homosexual and bisexual men. Am J Med 2000; 108: Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML. Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. Dis Colon Rectum 2002; 45: AIN in HIV-Positive Men JID 2004:190 (1 November) 1691
Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy
ACTA BIOMED 2007; 78: 36-40 Mattioli 1885 O R I G I N A L A R T I C L E Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy
More informationCytyc Corporation - Case Presentation Archive - June 2003
ThinPrep General Cytology History: Asymptomatic 35 Year Old Male Specimen type: Anal Cytology - This specimen was collected using a Dacron swab under proctoscopic visualization. This case was provided
More informationHPV-related papillomatous-condylomatous lesions in female anogenital area
HPV-related papillomatous-condylomatous lesions in female anogenital area Theo Panoskaltsis MD, FRCOG, CCST (UK) Epidemiology Anal cancer is increasing in both men and women Groups at risk: - HIV (+)
More informationHUMAN PAPILLOMAVIRUS INFECTION IN WOMEN INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS
HUMAN PAPILLOMAVIRUS INFECTION IN WOMEN INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS XIAO-WEI SUN, M.D., LOUISE KUHN, PH.D., TEDD V. ELLERBROCK, M.D., MARY ANN CHIASSON, DR.P.H., TIMOTHY J. BUSH, B.A.,
More informationHIV-infected men and women. Joel Palefsky, M.D. University of California, San Francisco
Anal cytology and anal cancer in HIV-infected men and women. Joel Palefsky, M.D. University of California, San Francisco April 10, 2010 Disclosures Merck and Co: Research grant support, advisory boards
More informationShould Anal Pap Smears Be a Standard of Care in HIV Management?
Should Anal Pap Smears Be a Standard of Care in HIV Management? Gordon Dickinson, M.D., FACP Professor of Medicine and Chief Infectious Diseases, Miller School of Medicine Short Answer: NO But 15-20 HPV
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationHCT Medical Policy. High-Resolution Anoscopy for Evaluation of Anal Lesions Policy # HCT109 Current Effective Date: 10/30/2014.
HCT Medical Policy High-Resolution Anoscopy for Evaluation of Anal Lesions Policy # HCT109 Current Effective Date: 10/30/2014 Medical Policies are developed by HealthyCT to assist in administering plan
More informationHuman Papillomavirus Prevalence, Viral Load and Cervical Intraepithelial Neoplasia in HIV-Infected Women
BJID 2002; 6 (June) 129 Human Papillomavirus Prevalence, Viral Load and Cervical Intraepithelial Neoplasia in HIV-Infected Women José E. Levi, Maria C.S. Fink, Cynthia L.M. Canto, Nadily Carretiero, Regina
More informationMEDICAL POLICY EFFECTIVE DATE: 12/20/12 REVISED DATE: 11/21/13, 10/16/14 SUBJECT: HIGH RESOLUTION ANOSCOPY
MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationAnal Cytology as a Screening Tool for Early Detection of Anal Dysplasia in HIV-infected Women
Anal Cytology as a Screening Tool for Early Detection of Anal Dysplasia in HIV-infected Women ANDREA GINGELMAIER, TOBIAS WEISSENBACHER, BERND KOST, RALPH KAESTNER, MILENA SOVRIC, IOANNIS MYLONAS, KLAUS
More informationFaculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
More informationHPV infection and intraepithelial lesions from the anal region: how to diagnose?
HPV infection and intraepithelial lesions from the anal region: how to diagnose? Review Article ABSTRACT In the last years, the prevalence of HPV infection in the anal region has increased, especially
More informationThe society for lower genital tract disorders since 1964.
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationHigh Prevalence of High Grade Anal Intraepithelial Neoplasia in HIV-infected Women Screened for Anal Cancer ACCEPTED
JAIDS Journal of Acquired Immune Deficiency Syndromes Publish Ahead of Print DOI: 10.1097/QAI.0b013e318251afd9 High Prevalence of High Grade Anal Intraepithelial Neoplasia in HIV-infected Women Screened
More informationHPV AND CERVICAL CANCER
HPV AND CERVICAL CANCER DR SANDJONG TIECHOU ISAAC DELON Postgraduate Training in Reproductive Health Research Faculty of Medicine, University of Yaoundé 2007 INTRODUCTION CERVICAL CANCER IS THE SECOND
More informationAnal cytological abnormalities and anal HPV infection in men with Centers for Disease Control
174 Original article University of California San Francisco, San Francisco, CA 94143, USA J M Palefsky E A Holly M L Ralston S P Arthur C J Hogeboom T M Darragh Correspondence to: Dr Joel Palefsky, Department
More informationHPV Testing & Cervical Cancer Screening:
HPV Testing & Cervical Cancer Screening: Are they linked? By William Chapman, MD, FRCPC Screening for precursor lesions of cervical cancer by the Papanicolaou (Pap) smear has been one of the greatest success
More informationGenital Dysplasia in Women Infected with Human Immunodeficiency Virus
Genital Dysplasia in Women Infected with Human Immunodeficiency Virus Gregory Taylor, MD, Tracy Wolff, MD, Niharika Khanna, MD, Priscilla Furth, MD, and Patricia Langenberg, PhD* Background: Women infected
More information!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationMEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY
MEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationThe prevalence of human papilloma virus in the anal region of male Chinese attendees in three public sexually transmitted disease clinics in Hong Kong
Hong Kong J. Dermatol. Venereol. (2011) 19, 6-13 Original Article The prevalence of human papilloma virus in the anal region of male Chinese attendees in three public sexually transmitted disease clinics
More informationEffect of HIV Infection on Atypical Squamous Cells of Undetermined Significance
MAJOR ARTICLE HIV/AIDS Effect of HIV Infection on Atypical Squamous Cells of Undetermined Significance Ann Duerr, 1 Pangaja Paramsothy, 2 Denise J. Jamieson, 3 Charles M. Heilig, 3 Robert S. Klein, 4 Susan
More informationHuman Papillomavirus (HPV) in Patients with HIV.
Human Papillomavirus (HPV) in Patients with HIV www.hivguidelines.org Purpose of the Guideline Increase the numbers of NYS residents with HIV who are screened for HPV-related dysplasia and managed effectively.
More informationTreatment of High-Grade Anal Dysplasia. Ross D. Cranston MB ChB MD FRCP Fundació Lluita contra la Sida
Treatment of High-Grade Anal Dysplasia Ross D. Cranston MB ChB MD FRCP Fundació Lluita contra la Sida Context What is the problem? What are we doing about it? What are the ongoing issues? Incidence rate
More informationWOMEN'S INTERAGENCY HIV STUDY
WOMEN'S INTERAGENCY HIV STUDY SECTION 22: ANAL SUBSTUDY PROTOCOL A. HYPOTHESES 1. Risk factors for anal HPV infection in women include receptive anal intercourse, smoking, cervical HPV infection, HIV positivity,
More informationHigh Rates of Anal High-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Who Do Not Meet Screening Guidelines
Clinical Infectious Diseases MAJOR ARTICLE High Rates of Anal High-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Who Do Not Meet Screening Guidelines Michael Gaisa, 1 Fanny Ita-Nagy, 1 Keith
More informationObjectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies
Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives
More informationMEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY EFFECTIVE DATE: 12/20/12 REVISED DATE: 11/21/13, 10/16/14, 09/17/15, 9/15/16 ARCHIVED DATE: 09/21/17
MEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationTHE PERFORMANCE OF CEPHEID XPERT HPV
THE PERFORMANCE OF CEPHEID XPERT HPV Zizipho Z.A Mbulawa, Timothy Wilkin, Bridgette J. Goeieman, Eefje Jong, Pamela Michelow, Avril Swarts, Jennifer S. Smith, Patricia Kegorilwe, Cynthia S. Firnhaber,
More informationAnal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors.
Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. Laurent Abramowitz, Dalila Benabderrahmane, Philippe Ravaud,
More informationDisclosures Teresa M Darragh, MD
Below the Belt: Screening for HPV-associated Cancers Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Disclosures Teresa M Darragh, MD Hologic: Research
More informationUpdate on Anal HPV. Medical Management of AIDS. December 9, Joel Palefsky Department of Medicine University of California, San Francisco
Update on Anal HPV Medical Management of AIDS December 9, 2017 Joel Palefsky Department of Medicine University of California, San Francisco Disclosures Merck and Co- research and travel support Antiva
More informationHPV Epidemiology and Natural History
HPV Epidemiology and Natural History Rachel Winer, PhD, MPH Associate Professor Department of Epidemiology University of Washington School of Public Health rlw@uw.edu Human Papillomavirus (HPV) DNA virus
More informationBottoms UP HIV and Anal Cancer from Screening to Prevention
Bottoms UP HIV and Anal Cancer from Screening to Prevention Paul MacPherson PhD, MD, FRCPC Associate Professor Division of Infectious Diseases University of Ottawa The New Reality Normal or near-normal
More informationAnal Cancer and HPV Related Tumor Prevention
Anal Cancer and HPV Related Tumor Prevention Timothy J. Wilkin, MD, MPH Associate Professor of Medicine Weill Cornell Medicine New York, New York Learning Objectives After attending this presentation,
More informationAtypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing
Anatomic Pathology / ATYPICAL GLANDULAR CELLS AND HUMAN PAPILLOMAVIRUS Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing Jeffrey F. Krane,
More informationStudy Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationWHAT CAUSES CERVICAL AND ANAL CANCER?
Harvard Center for Risk Analysis FEBRUARY 2000 Volume 8 Issue 2 Risk in Perspective Preventing Cervical and Anal Cancer in HIV-Positive Women and Men: Using Disease- Specific Models to Develop Clinical
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,
More informationHuman Papillomavirus. Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita
Human Papillomavirus Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita What is Genital HPV Infection Human papillomavirus is
More informationJean Anderson, MD Catherine Sewell, MD, MPH
Jean Anderson, MD Catherine Sewell, MD, MPH To review diagnosis and management of HPV disease in the setting of HIV infection and address controversies HIV-infected women have: higher prevalence and incidence
More informationNews. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM
Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND
More informationAbsolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women
Absolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women 2145 Philip E. Castle, Ph.D., M.P.H. 1 Sholom Wacholder, Ph.D. 1 Mark E. Sherman,
More informationCervical Precancer: Evaluation and Management
TAJ June 2002; Volume 15 Number 1 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review fam Cervical Precancer: Evaluation and Management SM Khodeza Nahar Begum 1 Abstract Carcinoma of
More informationHPV & RELATED DISEASES
GAY MEN, HPV & ANAL CANCER THEBOTTOMLINE.ORG.AU HPV & RELATED DISEASES WHAT IS HPV? The Human Papilloma Virus (HPV) is not one virus, but a family of about 200 different ones that cause common warts, genital
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent
More informationOBJECTIVES. Emerging Laboratory Diagnostic Options for Sexually-transmitted Infections
Emerging Laboratory Diagnostic Options for Sexually-transmitted Infections OBJECTIVES I. Appreciate the changing epidemiology of trichomoniasis and clinician ordering patterns on the basis of improved
More informationCervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
More informationCircumcision and penile human papillomavirus prevalence in human immunodeficiency virus-infected men: heterosexual and men who have sex with men
ORIGINAL ARTICLE EPIDEMIOLOGY Circumcision and penile human papillomavirus prevalence in human immunodeficiency virus-infected men: heterosexual and men who have sex with men M. P. Canadas 1,2, L. Darwich
More informationEmerging Laboratory Diagnostic Options for Sexually-transmitted Infections
Emerging Laboratory Diagnostic Options for Sexually-transmitted Infections Erik Munson Wheaton Franciscan Laboratory Marquette University Milwaukee, Wisconsin 1 OBJECTIVES I. Appreciate the changing epidemiology
More informationWhat is a Pap smear?
Pap smear What is a Pap smear? A Pap smear is a test that checks for changes in the cells of your cervix. The cervix is the lower part of the uterus that opens into the vagina. Developed over forty years
More informationHuman Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Human Papillomaviruses
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More informationBiomed Environ Sci, 2015; 28(1): 80-84
80 Biomed Environ Sci, 2015; 28(1): 80-84 Letter to the Editor Assessing the Effectiveness of a Cervical Cancer Screening Program in a Hospital-based Study* YANG Yi1, LANG Jing He1, WANG You Fang1, CHENG
More informationAnal Dysplasia Screening
Ontario Health Technology Assessment Series 2007; Vol. 7, No. 4 Anal Dysplasia Screening An Evidence-Based Analysis June 2007 Medical Advisory Secretariat Ministry of Health and Long-Term Care Suggested
More information- ii - Rights c
- ii - Rights c - iii - Preface Preface to the third edition Since the first edition of the HPV Information Centre, GLOBOCAN, one of the landmark products of the International Agency for Research on Cancer
More informationHPV infections and potential outcomes
CONTENTS Preface by Silvia de Sanjosé... 33 Preface by Jacob Bornstein... 37 Author s note... 39 Acknowledgments... 45 CHAPTER 1 HPV infections and potential outcomes HPV: What it is, where it is and what
More informationDevelopment and Duration of Human Papillomavirus Lesions, after Initial Infection
MAJOR ARTICLE Development and Duration of Human Papillomavirus Lesions, after Initial Infection Rachel L. Winer, 1 Nancy B. Kiviat, 2 James P. Hughes, 3 Diane E. Adam, 1 Shu-Kuang Lee, 3 Jane M. Kuypers,
More informationORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION Prevalence of Anal Intraepithelial Neoplasia Defined by Anal Cytology Screening and High-Resolution Anoscopy in a Primary Care Population of HIV-Infected Men and Women Stephen E.
More informationChapter 10: Pap Test Results
Chapter 10: Pap Test Results On completion of this section, the learner will be able to: 1. Identify how Pap test results are interpreted and the reasons for normal and abnormal results. 2. Describe the
More informationORIGINAL ARTICLES. Utilisation and outcomes of cervical cancer prevention services among HIV-infected women in Cape Town. Methods
Utilisation and outcomes of cervical cancer prevention services among HIV-infected women in Cape Town Priya Batra, Louise Kuhn, Lynette Denny Objective. An audit of outcomes of cervical cancer screening
More informationHow might we implement screening for anal cancer in HIV-positive patients?
Objective How might we implement screening for anal cancer in HIV-positive patients? Identify the elements required to set up an anal cancer screening and prevention program J. Michael Berry, MD Associate
More informationCytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches.
Cytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches. Fadi W. Abdul-Karim MD MEd. Professor of Pathology. Vice chair for education. Robert Tomsich Pathology and Lab Med
More informationSESSION J4. What's Next? Managing Abnormal PAPs in 2014
37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION J4 What's Next? Managing Abnormal PAPs in 2014 Session Description: Linda Eckert, MD Review current guidelines
More informationHuman Papillomavirus
Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and
More informationCancer in the LGBTQ Community. Katie Imborek, MD Clinical Assistant Professor University of Iowa Department of Family Medicine
+ Cancer in the LGBTQ Community Katie Imborek, MD Clinical Assistant Professor University of Iowa Department of Family Medicine + Objectives Discuss the possible reasons that LGBTQ people have a disproportionate
More informationAlthough rare, a significant increase in incidence
Original Research Concurrent Anal Human Papillomavirus and Abnormal Anal Cytology in Women With Known Cervical Dysplasia Jacqueline Lammé, MD, Tina Pattaratornkosohn, MD, Joselyn Mercado-Abadie, MD, Addie
More informationIS39 CP6108 [1]
112 9 26 2017 40 2018:28:112-118 (human papillomavirus, HPV) DNA 100 16 18 31 33 35 39 45 51 52 56 58 59 68 6 11 26 40 42 53 54 55 61 62 64 66 67 69 70 71 72 73 81 82 83 84 IS39 CP6108 ( ) [1] 2012 588,000
More informationHPV Genotyping: A New Dimension in Cervical Cancer Screening Tests
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests Lee P. Shulman MD The Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief, Division of Clinical Genetics Feinberg School
More informationRESEARCH ARTICLE. Kaori Okayama 1, Mitsuaki Okodo 2 *, Hiroshi Kitamura 3, Ichiro Itoda 4. Abstract. Introduction
DOI:10.22034/APJCP.2017.18.11.3173 Significance of the Cytological Signs of HPV Infection RESEARCH ARTICLE Significance of the Cytological Signs of Human Papillomavirus Infection in Anal Pap Smears of
More informationThe incidence of anal human papillomavirus. Anal Cancer and Screening Guidelines for Human Papillomavirus in Men
Anal Cancer and Screening Guidelines for Human Papillomavirus in Men Richard A. Ortoski, DO Christine S. Kell, PhD The association between human papillomavirus (HPV) and anal cancer and the similarities
More informationAtypical squamous cells. The case for HPV testing
OBG MANAGEMENT FOCUS ON CERVICAL DISEASE BY J. THOMAS COX, MD ASC-US is most often due to transient changes or HPV. HPV-positive ASC-US is 12.5 to 23 times more likely to be associated with CIN 2,3 on
More informationCervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH
Cervical Testing and Results Management An Evidenced-Based Approach April 22nd, 2010 Debora Bear, MSN, MPH Assistant Medical Director for Planned Parenthood of New Mexico, Inc. Burden of cervical cancer
More informationInternational Journal of Biological & Medical Research
Int J Biol Med Res. ; 2(3): 757-761 Int J Biol Med Res www.biomedscidirect.com Volume 2, Issue 3, July BioMedSciDirect Publications Contents lists available at BioMedSciDirect Publications International
More informationHPV Transmission. Rachel Winer, PhD, MPH Department of Epidemiology University of Washington
HPV Transmission Rachel Winer, PhD, MPH Department of Epidemiology University of Washington rlw@u.washington.edu Disclosure Information I have no financial relationships to disclose. Human Papillomavirus
More informationA Guide To Understanding Your Cervical Screening Test Results
A Guide To Understanding Your Cervical Screening Test Results INTRODUCTION This booklet provides you with information to help you better understand your Cervical Screening Test results. Your healthcare
More informationPrevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea
RESEARCH COMMUNICATION Prevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea Kidong Kim 1, Jin Ju Kim 2,3, Sun Mie
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationPrevalence of human papillomavirus in men who have sex with men in the era of an effective vaccine; a call to act
DOI: 10.1111/hiv.12150 ORIGINAL RESEARCH Prevalence of human papillomavirus in men who have sex with men in the era of an effective vaccine; a call to act C Sadlier, 1 D Rowley, 1 D Morley, 1 S Surah,
More informationGUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED
GUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED This guideline is a revised version of the guideline developed in February 2000, by the Cervical Cancer Screening Working Group. This revised version
More informationUK NATIONAL SCREENING COMMITTEE. Screening for Anal Cancer. 6 June 2013
UK NATIONAL SCREENING COMMITTEE Screening for Anal Cancer 6 June 2013 Aim 1. To agree the UK National Screening Committee s (UK NSC) formal policy position on screening for anal cancer. Background 2. A
More informationThe Anal Canal: an Important Transition Zone for Rectal Microbicide Development
The Anal Canal: an Important Transition Zone for Rectal Microbicide Development Ross D. Cranston MD FRCP Assistant Professor University of Pittsburgh Plan Anal canal Comparison with the rectum Common anal
More informationUnderstanding Your Pap Test Results
Understanding Your Pap Test Results Most laboratories in the United States use a standard set of terms called the Bethesda System to report pap test results. Normal: Pap samples that have no cell abnormalities
More informationGuidance Document on HPV Vaccination in Public HIV and STI Clinics
Guidance Document on HPV Vaccination in Public HIV and STI Clinics Version 2.0 26 th October 2018 Contents 1. Introduction and Background... 2 1.1 Introduction... 2 1.2 Background... 2 2. Safety and efficacy
More informationNo HPV High Risk Screening with Genotyping. CPT Code: If Result is NOT DETECTED (x3) If Results is DETECTED (Genotype reported)
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 117 August 6, 2013 HPV High Risk Screening with Genotyping Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Director, Molecular Pathology
More informationAnal intraepithelial neoplasia in HIV positive people
Sex Transm Inf 2001;77:327 331 327 Review Department of Oncology, Chelsea and Westminster Hospital, Fulham Road, London SW10 9NH, UK F Martin Mark Bower Correspondence to: Mark Bower m.bower@ic.ac.uk Accepted
More informationPAP smear. (Papanicolaou Test)
PAP smear (Papanicolaou Test) Is a screening test to prevent/ detect cancerous processes in endocervical canal It reduces the mortality caused by cervical cancer up to 80% M. Arbyn; et al. (2010). "European
More informationVasile Goldiş Western University of Arad, Faculty of Medicine, Obstetrics- Gynecology Department, Romania b
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Cervical Intraepithelial Neoplasia in the Dr. Salvator Vuia Clinical Obstetrics and Gynecology Hospital - Arad During the 2000-2009 Period Voicu
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationHPV-DNA Test Kit in Cervical Scrapes or
Infectious Diseases in Obstetrics and Gynecology 2:126-129 (I 994) (C) 1994 Wiley-Liss, Inc. Detection of Human Papillomavirus DNA by AffiProbe HPV-DNA Test Kit in Cervical Scrapes or Biopsies-Histopathologic
More informationGoals. In the News. Primary HPV Screening 3/9/2015. Your PAP and HPV Update Primary HPV Testing- Screening Intervals- HPV Vaccine Updates-
Your PAP and HPV Update 2015 Connie Mao, MD University of Washington Goals Primary HPV Testing- Is it time to stop doing pap smears? Screening Intervals- Should patients have a choice? HPV Vaccine Updates-
More informationThe Korean Journal of Cytopathology 13(1): 14-20, 2002
13 1 The Korean Journal of Cytopathology 13(1): 14-20, 2002 : ASCUS 1941 Papanicolaou. The Bethesda System(TBS) 1) 1988, atypical squamous cells of undetermined significance(ascus), low-grade squamous
More informationHPV FREE IDAHO. Fundamentals of HPV Bill Atkinson, MD MPH
HPV FREE IDAHO Fundamentals of HPV Bill Atkinson, MD MPH You are the Key to HPV Cancer Prevention William Atkinson, MD, MPH Associate Director for Immunization Education Immunization Action Coalition February
More information3rd IAS Conference on HIV Pathogenesis and Treatment. Poster Number Abstract #
3rd IAS Conference on HIV Pathogenesis and Treatment 24 27 July 2005, Rio de Janeiro, Brazil Poster Number Abstract # TuFo0106 TuFo0106 Characterization of Anemia in HIV-infected (HIV+) Subjects Treated
More informationPromoting early detection of HIV and anal dysplasia in Thai men who have sex with men Phanuphak, N.
UvA-DARE (Digital Academic Repository) Promoting early detection of HIV and anal dysplasia in Thai men who have sex with men Phanuphak, N. Link to publication Citation for published version (APA): Phanuphak,
More informationFocus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection
HPV infection in 2014 Papillomaviruses (HPV) are non-cultivable viruses with circular DNA. They can establish productive infections in the skin (warts) and in mucous membranes (genitals, larynx, etc.).
More information